Mar 15, 2000 | NEWS
Pharming’s first Phase II clinical trialA research study that tests new treatments or approaches in people. More for Pompe’s disease finalised, showing survival, skeletal muscleMuscles that control movement and are commonly affected in Pompe disease. More regeneration...
Dec 5, 1999 | NEWS
New York University Medical Center Frank Martiniuk, Ph.D. A collaborative effort to test animal models with enzymeA protein that helps the body carry out chemical reactions. More and gene replacement is underway. Dr. Martiniuk is sending the human gene and acid...
Aug 4, 1999 | NEWS
Applied Biological Sciences Systemic correction of the muscle disorder glycogen storage disease type IIThe scientific name for Pompe disease, based on how glycogen builds up in the body. More after hepatic targeting of a modified adenovirus vectorA delivery system,...
Aug 3, 1999 | NEWS
News Release by Karyn Hede Duke Medical Center News Office August 2, 1999 Using a modified virus to deliver a therapeutic gene, scientists at Duke University Medical Center have shown that, in mice, they can reverse the damage caused by an inherited muscle-wasting...
Jul 4, 1999 | NEWS
The first IPA Conference was held on July 2-4, 1999, in Naarden, the Netherlands. The meeting was attended by over 60 participants from 11 countries which included members of the medical and scientific community, patient organizations and industry. Presentations...
Jun 30, 1999 | NEWS
The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 Synpac Pharmaceuticals Limited Cambois, Bedlington, Northumberland NE22 7DB...
Jun 26, 1999 | NEWS
The following article by Laura Spinney appears in BioMednews Reports (6- 25-99,#57) Glycogen storage disease type IIThe scientific name for Pompe disease, based on how glycogen builds up in the body. More causes enlargement of certain muscles, particularly the heart...
Jan 18, 1999 | NEWS
Orphan Drug Designation A drug becomes an “orphan” when it receives orphan designation from the Office of Orphan Products Development, FDA. An orphan drug is a drug intended to treat diseases or conditions affecting fewer than 200,000 people per year in the United...
Jan 4, 1999 | NEWS
Following is background information and a Q & A released by the Pharming/Genzyme LLC on important issues concerning clinical trialsA research study that tests new treatments or approaches in people. More for enzymeA protein that helps the body carry out chemical...
Oct 15, 1998 | NEWS
Leiden, the Netherlands/Cambridge, Mass., October 14, 1998—Pharming Group N.V. (Easdaq: PHAR), the Netherlands biopharmaceutical company, and the American biotechnology company Genzyme General (Nasdaq: GENZ), has created a joint venture to develop and commercialize...
